32.21 USD
+0.25
0.78%
At close Apr 21, 4:00 PM EDT
After hours
32.21
+0.00
0.00%
1 day
0.78%
5 days
-1.59%
1 month
-17.58%
3 months
-32.88%
6 months
-20.47%
Year to date
-27.29%
1 year
-41.97%
5 years
43.35%
10 years
-33.67%
 

About: Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Employees: 7,367

0
Funds holding %
of 7,419 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

176% more call options, than puts

Call options by funds: $80.4M | Put options by funds: $29.1M

78% more repeat investments, than reductions

Existing positions increased: 130 | Existing positions reduced: 73

13% more first-time investments, than exits

New positions opened: 53 | Existing positions closed: 47

1.92% more ownership

Funds ownership: 108.58% [Q3] → 110.51% (+1.92%) [Q4]

4% more capital invested

Capital invested by funds: $2.61B [Q3] → $2.71B (+$101M) [Q4]

1% more funds holding

Funds holding: 283 [Q3] → 285 (+2) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$64
99%
upside
Avg. target
$64
99%
upside
High target
$64
99%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
Needham
Mike Matson
22% 1-year accuracy
27 / 121 met price target
99%upside
$64
Buy
Reiterated
9 Apr 2025

Financial journalist opinion

Based on 3 articles about ENOV published over the past 30 days

Neutral
GlobeNewsWire
4 days ago
Enovis to Host First Quarter 2025 Results Conference Call on May 8th
Wilimington, DE, April 17, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its first quarter 2025 financial results on Thursday, May 8th, 2025 at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at www.enovis.com.
Enovis to Host First Quarter 2025 Results Conference Call on May 8th
Neutral
GlobeNewsWire
2 weeks ago
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer
WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company's 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at the Annual Meeting. Enovis also reiterated its expectations for first quarter revenues to be in the range of $555 to $563 million and adjusted EBITDA in the range of $97 to $100 million.
Enovis Announces Appointment of Damien McDonald as Chief Executive Officer
Neutral
GlobeNewsWire
3 weeks ago
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025
WILMINGTON, DE, March 25, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will feature its expanding portfolio of foot and ankle solutions at this year's American College of Foot & Ankle Surgeons (ACFAS) Annual Scientific Conference in Phoenix, Ariz., taking place March 27-30.
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025
Neutral
GlobeNewsWire
1 month ago
Enovis to Participate in Upcoming Investor Conferences
Wilmington, DE, March 05, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences:
Enovis to Participate in Upcoming Investor Conferences
Positive
Seeking Alpha
1 month ago
Enovis Continues To Languish Despite Decent Financial Results
Enovis shares have continued to languish despite on-target financial performance, with Q4'24 results meeting expectations and featuring double-digit growth in its Reconstructive business. Enovis' Recon business outperformed its larger rivals in Q4, with double-digit growth in global hips and knees and double-digit growth in U.S. knees as well. Uncertainty from an unexpected CEO transition and potential 2025 tariffs only add to market hesitation.
Enovis Continues To Languish Despite Decent Financial Results
Neutral
Seeking Alpha
1 month ago
Enovis Corporation (ENOV) Q4 2024 Earnings Call Transcript
Enovis Corporation (NYSE:ENOV ) Q4 2024 Results Conference Call February 26, 2025 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Berry - Senior VP & CFO Conference Call Participants Vic Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Jeff Johnson - Baird Brandon Vazquez - William Blair Danielle Antalffy - UBS Mike Matson - Needham & Company Caitlin Cronin - Canaccord Jason Wittes - ROTH Operator Good day, and welcome to the Enovis Fourth Quarter 2024 Earnings Conference Call. All participants will be in a listen-only mode.
Enovis Corporation (ENOV) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates
Enovis (ENOV) came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.92 per share. This compares to earnings of $0.79 per share a year ago.
Enovis (ENOV) Q4 Earnings and Revenues Surpass Estimates
Neutral
GlobeNewsWire
1 month ago
Enovis Announces Fourth Quarter and Full Year 2024 Results
Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the fourth quarter and full year ended December 31, 2024. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET.
Enovis Announces Fourth Quarter and Full Year 2024 Results
Neutral
GlobeNewsWire
1 month ago
Enovis Announces Planned CEO Succession Process
Wilmington, DE, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), a leader in medical technology innovation, announced today that Matt Trerotola has informed the Board of Directors (the “Board”) of his intention to retire from his position as Chief Executive Officer (CEO) of Enovis, effective upon his successor being appointed by the Board and assuming the position as CEO.  As part of the Company's succession planning process, the Board is actively working with an executive search firm to identify a growth-oriented MedTech leader who shares our passion for continuous improvement and patient outcomes, to serve as the Company's next CEO.
Enovis Announces Planned CEO Succession Process
Neutral
Zacks Investment Research
2 months ago
Zacks Industry Outlook Enovis, Omnicell and Phreesia
Enovis, Omnicell and Phreesia have been highlighted in this Industry Outlook article.
Zacks Industry Outlook Enovis, Omnicell and Phreesia
Charts implemented using Lightweight Charts™